Introduction
Lung cancer is the leading cause of cancer death worldwide. 1, 2 There are more than 10 million deaths from lung cancer every year, largely because of the lack of effective early diagnosis and treatment. Despite improvements in the availability and sophistication of lung cancer treatment regimens, such as radiotherapy, chemotherapy, and surgery, the 5-year survival rate remains only 15% and has not increased significantly over the past 20 years. 3 Studies of the molecular mechanisms of lung cancer have led investigators and clinicians to focus on gene therapy approaches. Unfortunately, most patients with lung cancer have been diagnosed with distant metastasis, 4, 5 which requires systemic treatment rather than local treatment. It is still difficult to apply gene therapy to systemic disease. 6 Genetic mutations in MCPH1 result in primary autosomal recessive microcephaly characterized by a significant reduction in brain size, clinical cortical dysplasia, and mental retardation. 7, 8 MCPH1 encodes a centrosomal protein containing three BRCA1 carboxy-terminal (BRCT) domains. BRCA1 belongs to the BRCT family of proteins that are involved in DNA repair. 9, 10 In addition, MCPH1 is associated with the cell damage response, apoptosis, and cell-cycle regulation.
MCPH1 acts as a tumor suppressor in a variety of cancer cells. 11 In humans, MCPH1 is located on chromosome 8p23.1, where loss of chromosomal region is very common in several malignancies such as breast and prostate cancer. In fact, previous submit your manuscript | www.dovepress.com
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Wu et al research demonstrated that MCPH1 is downregulated in a variety of cancer cells, including cervical cancer, breast cancer, and prostate cancer. 8, 12 Moreover, overexpression of MCPH1 can inhibit the epithelial-mesenchymal transition (EMT) of cervical cancer cells. 13 In addition, our previous studies revealed that MCPH1 is downregulated in lung cancer tissues, and it is also involved in the pathogenesis of lung cancer.
14,15 Therefore, we hypothesized that the absence or low-level expression of MCPH1 may play an important role in the initiation and progression of lung cancer.
In this study, we first evaluated relapse-free survival of patients with lung cancer and found that patients with highlevel MCPH1 expression had significantly longer relapsefree survival than those with low-level MCPH1 expression. Next, we studied the biological effects of MCPH1 in a lung cancer cell line and its possible mechanism. Our findings revealed that MCPH1 overexpression inhibits lung cancer cell migration and invasion by blocking Mdm2-mediated ubiquitination of p53.
Materials and methods survival analysis
Expression profiling microarray data for human lung cancer clinical specimens were collected from the National Center for Biotechnology Information Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). Relative MCPH1 expression for two microarray datasets, namely, GSE8894 and GSE31210, was assessed with the GEO2R interface (http://www.ncbi.nlm.nih.gov/geo/geo2r/). Survival analysis for non-small-cell lung cancer (NSCLC) patients with different MCPH1 expression levels was performed using the KM plotter database. The prognostic value of MCPH1 was assessed by splitting the patient samples into two groups according to median expression. The survival rate was analyzed with SPSS 17.0 software (IBM Corp., Armonk, NY, USA). Ultimately, 138 patients (in GSE8894) and 204 patients (in GSE31210) were analyzed. This study was approved by the Ethics Committee of Chongqing Medical University. Written informed consent was waived by the Ethics Committee due to data being de-identified and anonymous.
cell culture and transfection
The A549 cell lines were purchased from Cell Bank, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai. A549 human NSCLC cells were cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific), penicillin (50 U/mL), and streptomycin (50 µg/mL; Thermo Fisher Scientific). Cells were maintained at 37°C in 5% CO 2 moist air. The constructed pcDNA3.1(-) MCPH1 plasmid was used for cell transfection. 15 The same number of cells was plated in 24-well and 6-well plates and grown to 80% confluency. Cells in the 24-well plates were transfected with 0.5 µg pcDNA3.1(-)MCPH1 or empty vector. Cells in the 6-well plates were transfected with 1.0 µg pcDNA3.1(-)MCPH1 or empty vector. The specified amounts of vectors were combined in Opti-MEM™ medium (Thermo Fisher Scientific) with Lipofectamine 2000. The solution was incubated for 30 min at room temperature and then added to the cultured cells. The medium was changed to DMEM with 10% FBS after 4 to 6 h.
Wound healing assay
A horizontal line was drawn on the back of the 6-well plate. The cells (5 × 10 5 cells/well) were plated overnight in a 6-well plate. A 200 µL pipette tip was used to create a scratch wound across the cells on the plate, and then the plate was washed twice with PBS to remove any floating cells. Serum-free medium was replaced after 24 h, and the closing of each scratch wound was quantified under an inverted microscope.
analysis of cell migration and invasion
After 72 h, transfected A549 cells were diluted with serum-free DMEM containing 0.1% BSA. For the cell migration assay, transfected cells were inoculated into the upper compartment of a transwell chamber and incubated at 37°C for 48 h with the lower chamber, which contained 800 µL DMEM with 10% FBS. The cells were then fixed in methanol and stained with 0.1% crystal violet. The migrating cells in three randomly selected fields were counted using a light microscope.
For the cell invasion assay, the transfected A549 cells were inoculated into the upper transwell chamber with Matrigel (BD Biosciences, San Jose, CA, USA) and incubated at 37°C for 48 h with the lower chamber, which contained 800 µL DMEM with 10% FBS. The cells were then fixed in methanol and stained with 0.1% crystal violet. The invading cells in three randomly selected fields were counted using a light microscope.
Western blotting
Western blotting was performed as previously described. 15 The proteins were incubated with rabbit monoclonal antihuman IgG to MCPH1 (cat. no ab123361; 1:200 dilution; Abcam, Cambridge, UK), rabbit monoclonal anti-β-actin IgG (cat. no A0483; 1:100 dilution; Sigma-Aldrich Co., St Louis, MO, USA), rabbit polyclonal anti-Slug IgG (cat. no Ab27568; 1:2,000 dilution; Abcam), rabbit polyclonal anti-Snail IgG (cat. no Ab82846; 1:500 dilution; Abcam), 
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Overexpression of McPh1 inhibits the migration and invasion rabbit monoclonal anti-E-cadherin IgG (cat. no Ab133597; 1:2,000 dilution; Abcam), rabbit monoclonal anti-p53 (cat. no SAB1306667; 1:500 dilution; Sigma-Aldrich Co.), and mouse monoclonal anti-Mdm2 (cat. no M7815; 1:500 dilution; Sigma-Aldrich Co.).
statistical analysis
Data are expressed as the mean ± SD. Multiple groups of comparative analysis were conducted via one-way analysis of variance and the post hoc Tukey's test, with plasmid treatment as the between-subjects factor. All statistical analyses were performed with the SPSS 17.0 software. P , 0.05 was considered to reflect a significant difference.
Results
MCPH1 expression is associated with the survival of lung cancer patients. To study the role of MCPH1 in human lung cancer, microarray datasets with NSCLC or NSCLC specimens were collected from the GEO database. The KM plotter database was used to further investigate the association between MCPH1 expression and clinical outcome. Overall survival of patients with lung cancer was associated with high MCPH1 expression in both datasets (both P , 0.05; Figure 1 ). These results suggested that MCPH1 has a protective role in the development of lung cancer.
Overexpression of MCPH1 significantly inhibits a549 cell migration and invasion
It was recently demonstrated that MCPH1 overexpression inhibits cell proliferation and promotes apoptosis of lung cancer cells.
9, 10 We therefore tested whether MCPH1 could affect lung cancer cell migration and invasion. A549 cells were transfected with pcDNA3.1(-)MCPH1 or empty vector. The wound width of the gap was 100 µm, and wound healing was observed at 0, 24, and 48 h. The wound healing assay indicated that MCPH1 overexpression reduced the migration of A549 cells (Figure 2A ).
The effect of MCPH1 overexpression on cell migration was then assessed using a transwell assay. The number of A549 cells that migrated through the micropore in the pcDNA3.1(-)MCPH1 group was 25.333 ± 3.7564, which was significantly less than that for untreated control cells (87 ± 5.0332; P = 0.0007) and for cells transfected with pcDNA3.1 (88.666 ± 5.7831; P = 0.0037; Figure 2B ). This finding also indicated that overexpression of MCPH1 inhibited the migration of A549 cells.
The invasion of A549 cells transfected with pcDNA3.1(-) MCPH1 or empty vector was analyzed with a cell invasion assay. The number of A549 cells that migrated through the micropore in the pcDNA3.1(-)MCPH1 group was 11.666 ± 1.763, which was significantly less than for the untreated control cells (31 ± 3.055; P = 0.0027) and for cells transfected with pcDNA3.1 (27 ± 1.154; P = 0.0009; Figure 2C ). This result indicated that overexpression of MCPH1 inhibited the invasion capacity of A549 cells.
Overexpression of McPh1 inhibits migration and invasion of lung cancer cells through the accumulation of p53
Our results, to this point, indicated that MCPH1 inhibits the migration and invasion capacities of A549 cells. Cell migration and invasion is associated with certain proteins, such as Slug, Snail, and E-cadherin. 16 In addition, it has been reported that p53 may suppress the EMT via the p53/Mdm2 pathway, and MCPH1 can regulate p53 protein.
17,18 Therefore, we measured the cellular levels of these proteins after MCPH1 overexpression in A549 cells. The results demonstrated that Slug expression in cells transfected with pcDNA3.1(-)MCPH1 was significantly reduced compared with that in untreated Figure 3A and B). Snail expression in cells transfected with pcDNA3.1(-)MCPH1 was also significantly reduced compared with that in untreated control cells or cells transfected with pcDNA3.1 (P = 0.0152 and P = 0.0388, respectively; Figure 3A and B). By contrast, the expression of E-cadherin, a factor that antagonizes the EMT, was significantly increased in A549 cells that were transfected with pcDNA3.1(-)MCPH1 as compared with that in untreated control cells or cells transfected with pcDNA3.1 (P = 0.0042 and P = 0.0015, respectively; Figure 3A and B). These results indicated that MCPH1 overexpression inhibited A549 cell migration and invasion via regulation of the expression of several EMT regulators.
We next explored the pathways by which MCPH1 overexpression inhibits the EMT. Western blotting revealed that p53 expression in cells transfected with pcDNA3.1(-) MCPH1 was significantly increased compared with that in untreated control cells or cells transfected with pcDNA3.1 (P = 0.0058 and P = 0.006, respectively; Figure 3A and B). In addition, Mdm2, which also antagonizes the EMT, was significantly increased in cells transfected with pcD-NA3.1(-)MCPH1 compared with that in untreated control cells or cells transfected with pcDNA3.1 (P = 0.0017 and P , 0.0001, respectively; Figure 3A and B). These results indicated that MCPH1 overexpression may inhibit A549 cell migration and invasion via the upregulation of the cellular level p53. 
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Discussion
There are currently many studies of MCPH1 that mainly focused on its role in regulating cell-cycle and pro-apoptotic activities. Multiple studies have demonstrated that MCPH1 has an important role in controlling DNA damage signaling by regulating the ATM/ATR pathway, modifying chromosome structure, and participating in DNA repair. 19, 20 However, it has been demonstrated that, compared with normal tissues, several cancer tissues express much lower concentrations of MCPH1, such as lung cancer, cervical cancer, breast cancer, prostate cancer, and ovarian cancer. Based on these advances, we hypothesized that deletion or low-level expression of MCPH1 may participate in the development of tumors. However, previous studies have not investigated the potential contribution of MCPH1 mutations to lung cancer. In the present study, our initial results demonstrated that relatively high-level expression of MCPH1 is associated with improved clinicopathological parameters and increased survival of lung cancer patients, and thus, our subsequent studies focused on the role of MCPH1 expression in the migration and invasion potential of lung cancer cells and the underlying mechanism(s).
Previous studies have demonstrated that aberrant underexpression or the expression of MCPH1 is associated with the development of several cancers. [21] [22] [23] In addition, we reported that MCPH1 is expressed at lower levels in lung tissues and that overexpression of MCPH1 inhibits NSCLC cell proliferation. 14, 15 The present study suggests that MCPH1 plays a role in lung cancer development (Figure 1 ). Our current results confirm our hypothesis that MCPH1 deletion or its low-level expression contributes to the development of lung tumors (Figure 1 ).
Prior to our work, we saw that overexpression of MCPH1 inhibited A549 cell proliferation by increasing apoptosis 
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Wu et al and arresting the cell cycle in S and G2/M phases. 15 Next, to investigate other potential functions of MCPH1 in lung cancer cells, the effects of MCPH1 overexpression on migration and invasion were investigated in lung cancer cells. The results revealed that overexpression of MCPH1 inhibited the migration and invasion capacities of A549 cells (Figure 2 ). These results demonstrate that MCPH1 may function as a suppressor of lung tumorigenesis.
Our present study revealed that MCPH1 overexpression significantly inhibited cancer cell migration and invasion. EMT-associated proteins are key regulators involved in NSCLC migration and invasion. EMT is mainly regulated through the extracellular factor activation of intracellular signal transduction pathways, including those governed by TGF-β/Smads, TGF-β integrin, Hedgehog, Notch, Wnt/ β-catenin, MAPK, and PI3K/AKT. [24] [25] [26] [27] The activation of these signaling pathways upregulates genes encoding transcription factors that promote the expression of factors that promote the EMT, such as Snail, Slug, Twist1, Twist2, ZEB1, and ZEB2. [28] [29] [30] In addition, these transcription factors regulate the expression of EMT-associated marker proteins, such as Snail, which can bind directly to the promoter of E-cadherin and inhibit its transcription. [31] [32] [33] Interestingly, we discovered that MCPH1 overexpression inhibited Snail and Slug expression. However, overexpression of MCPH1 upregulated the expression of E-cadherin (Figure 3) . These results also indicated that MCPH1 overexpression inhibited the EMT of lung cancer cells.
A recent study reported that MCPH1, as a member of the discoidin domain receptor family, is a key regulator of the ATM/ATR pathway 10, 12, 34 and also contributes to the modification of chromosome structure REFs and to DNA repair REFs. Interestingly, another study reported that MCPH1 could induce the activation of the ATM/Chk2 and ATR/Chk1 pathways and the phosphorylation of H2AX, as well as delay the progression of cells entering S phase. 34 Also, MCPH1 regulates p53 stability by blocking its ubiquitination, which is mediated by Mdm2, and thus, MCPH1 acts as a posttranscriptional regulator of p53. 35, 36 Furthermore, p53 can regulate bcl-2 and bax gene expression as a tumor suppressor, and Mdm2 can promote the ubiquitination and degradation of Slug and Snail, which are pivotal transcription factors that drive cancer cell invasion. In the present study, overexpression of MCPH1 was shown to increase the expression of p53 and Mdm2. We postulate that MCPH1 overexpression may inhibit the migration and invasion of lung cancer cells by blocking Mdm2-mediated p53 ubiquitination (Figure 4 ).
In conclusion, our results strongly suggest that MCPH1 may be a crucial tumor suppressor gene, and thus a candidate therapeutic target for lung cancer. Overexpression of MCPH1 inhibited the migration and invasion of lung cancer cells. MCPH1 inhibited Snail and Slug by blocking Mdm2-mediated p53 ubiquitination, and thus inhibited the invasion and migration capacities of NSCLC cells. These data strongly suggest that MCPH1 may be a crucial tumor suppressor gene and a novel candidate therapeutic target for lung cancer. 
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